Atlas Trials

Alkermes, Inc.

82 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Alkermes, Inc.

RecordFirmDate
A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201) (NCT07755410)Alkermes, Inc.2026-08-01
A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304) (NCT07540897)Alkermes, Inc.2026-08-01
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2 (NCT07502443)Alkermes, Inc.2026-04-22
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 (NCT07455383)Alkermes, Inc.2026-04-06
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia (NCT06843590)Alkermes, Inc.2025-05-22
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia (NCT06767683)Alkermes, Inc.2025-01-27
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2 (NCT06555783)Alkermes, Inc.2024-07-26
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201) (NCT06358950)Alkermes, Inc.2024-03-24
Study of the Breast Milk Pharmacokinetics of Olanzapine and Samidorphan (NCT05547100)Alkermes, Inc.2022-09-14
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (NCT05303064)Alkermes, Inc.2022-06-30
Phase 1 ALKS 1140 in Healthy Adults (NCT05019105)Alkermes, Inc.2021-10-13
A 28 Day Parallel Group Study to Assess the Effects of RDN-929 (NCT03963973)Alkermes, Inc.2019-05-16
Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS) (NCT03919994)Alkermes, Inc.2019-03-28
Single and Multiple Ascending Dose and Food Effect PK Study in Healthy Adult and Elderly Subjects (NCT03668314)Alkermes, Inc.2018-10-10
A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD) (NCT03610048)Alkermes, Inc.2018-08-09
A Non-therapeutic Feasibility Study of the Radioligand [11C]-UCB-J for Imaging Synaptic Density (NCT03577262)Alkermes, Inc.2018-07-23
A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia (NCT03345979)Alkermes, Inc.2017-11-15

Track Alkermes, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.